Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.

Overall, the relative fluorescence intensities of these cancer cell lines, as calculated by the average of the IF stained cells, showed a trend consistent with the transcriptome database, confirming binding specificity of the PD-L1 antibody.

also in 53,322 other papers